Press Releases

<< Back
Printer Friendly Version View printer-friendly version
BeiGene to Present Data on BGB-3111 at the 14th International Conference on Malignant Lymphoma and to Host Conference Call

CAMBRIDGE, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that it will present updates on its BTK inhibitor BGB-3111 in three oral presentations and a poster at the upcoming 14th International Conference on Malignant Lymphoma (14-ICML). 14-ICML will take place June 14-17, 2017, in Lugano, Switzerland. Following its presentations, BeiGene will host an investor call and webcast to discuss the presented data and development program.

Oral Presentation, Abstract # 059

Title: Bruton’s Tyrosine Kinase (BTK) Inhibitor BGB-3111 Demonstrates High Very Good Partial Response (VGPR) Rate in Patients with Waldenström Macroglobulinemia (WM)

Presenter: Dr. Judith Trotman

Session: Session 4 - Targeting the BCR Pathways
Date & Time: Thursday, June 15, 2017, 4:00 PM CEST
Location: Room A, Cinema Corso and Aula Magna (Lugano University)

Oral Presentation, Abstract # OT06

Title: A Head-to-Head Phase 3 Study Comparing BGB-3111 and Ibrutinib in Patients with Waldenström Macroglobulinemia

Presenter: Dr. Christian Buske

Session: Ongoing Trials
Date & Time: Thursday, June 15, 2017, 6:05 PM CEST
Location: Auditorium (Lugano University)

Oral Presentation, Abstract # 103

Title: Safety and Activity of the Highly Specific BTK Inhibitor, BGB-3111 Plus Obinutuzumab in Patients (Pts) with Follicular Lymphoma (FL) and Chronic Lymphocytic Leukemia (CLL)

Presenter: Dr. Constantine Tam

Session: Session 7 - Advances in CLL
Date & Time: Friday, June 16, 2017, 11:50 AM CEST
Location: Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)

Poster, Abstract # 237

Title: High Overall Response Rate with the BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma: An Update on Safety and Activity

Presenter: Dr. John Seymour

Session Dates & Times: Wednesday, June 14, 12:30-6:30 PM CEST; Thursday, June 15, 8:30-6:30 PM CEST; Friday, June 16, 8:30-6:30 PM CEST
Location: Marquee

Investor Conference Call

Date & Time: Friday, June 16, 2017, 2:00 PM CEST (8:00 AM EDT, 8:00 PM China Standard Time)

Dial-in Numbers: 1-845-675-0437 or 1-866-519-4004 (US), 400-620-8038 or 800-819-0121 (China), +852 30186771 (Hong Kong), or +65 67135090 (International)

Conference ID Number: 33044427

A live webcast and replay will be available on BeiGene’s investor website, http://ir.beigene.com/. The dial-in replay will be available approximately two hours after the conference and will be available for two days following the event. It can be accessed by dialing 1-646-254-3697 (US), 400-632-2162 (China), +852 30512780 (Hong Kong), or +61 2 8199 0299 (International).

About BGB-3111

BGB-3111 is a potent and highly selective investigational small molecule inhibitor of BTK. BGB-3111 has demonstrated higher selectivity against BTK than ibrutinib (the only BTK inhibitor currently approved by the U.S. Food and Drug Administration and the European Medicines Agency) based on biochemical assays, higher exposure than ibrutinib based on their respective Phase I experience, and sustained 24-hour BTK occupancy in both the blood and the lymph node.

About BeiGene

BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 400 employees in mainland China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for the treatment of cancer. BeiGene is working to create combination solutions aimed at having both a meaningful and lasting impact on cancer patients.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the encouraging preclinical and clinical data of BGB-3111. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; BeiGene's ability to achieve market acceptance in the medical community necessary for commercial success; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct preclinical studies and clinical trials and manufacturing; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law. 

Investor/Media Contact

Lucy Li, Ph.D.
+1 781-801-1800
ir@beigene.com
media@beigene.com

Primary Logo

BeiGene, LTD.